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The Ebola virus (EBOV) trimeric envelope glycoprotein (GP)
precursors are cleaved into the receptor-binding GP1 and the
fusion-mediating GP2 subunits and incorporated into virions to
initiate infection. GP1 and GP2 form heterodimers that have 15
or two N-glycosylation sites (NGSs), respectively. Here we inves-
tigated the mechanism of how N-glycosylation contributes to
GP expression, maturation, and function. As reported before,
we found that, although GP1 NGSs are not critical, the two GP2
NGSs, Asn563 and Asn618, are essential for GP function. Further
analysis uncovered that Asn563 and Asn618 regulate GP pro-
cessing, demannosylation, oligomerization, and conformation.
Consequently, these two NGSs are required for GP incorpora-
tion into EBOV-like particles and HIV type 1 (HIV-1) pseudovi-
rions and determine viral transduction efficiency. Using
CRISPR/Cas9 technology, we knocked out the two classical endo-
plasmic reticulum chaperones calnexin (CNX) and/or calreticulin
(CRT) and found that both CNX and CRT increase GP expression.
Nevertheless, NGSs are not required for the GP interaction with
CNX or CRT. Together, we conclude that, although Asn563 and
Asn618 are not required for EBOV GP expression, they synergisti-
cally regulate its maturation, which determines its functionality.
The 2014 outbreak of Ebola hemorrhagic fever in West
Africa has resulted in the deaths of over 11,000 people and
represents the worst epidemic of this disease in history (1).
Ebola hemorrhagic fever is caused by Ebola viruses (EBOVs),4
members of Filoviridae, which can have a 90% rate of mortality
in humans and nonhuman primates (2). Filoviridae is com-
posed of two genera: EBOVs and Marburg viruses, which are
enveloped and have single, non-segmented, negative-sense
RNA genomes with a size of 19 kb (3). So far, five EBOV
species have been identified, including Zaire, Sudan, Bundibu-
gyo, Tai Forest, and Reston, which share 60% amino acid
identity. All of these isolates can cause diseases in humans,
except for the Reston strain, which is pathogenic in nonhuman
primates; the Zaire, Sudan, and Bundibugyo strains have been
very pathogenic in humans (2).
The EBOV genome encodes seven structural proteins and
one non-structural protein (3). As the only structural compo-
nent on the viral surface, the glycoprotein (GP) is responsible
for viral entry and initiation of infection (4, 5). EBOV GPs are
class I viral fusion proteins, a classification category that also
includes influenza viruses, paramyxoviruses, and retroviruses
(6). EBOV GP is unique because it also functions as an impor-
tant virulence factor that induces cytotoxic effects both in vivo
and in vitro (7). Thus, EBOV has evolved an RNA-editing
mechanism to regulate its GP expression through two open
reading frames (8, 9). Most transcripts (80%) are not RNA-ed-
ited and thus produce a truncated, secreted GP because of a
premature stop codon that plays a role in immune evasion (10).
The remaining transcripts are edited, which produces the full-
length precursor GP (GPpre) in the endoplasmic reticulum (ER).
GPpre is further processed into a fully glycosylated uncleaved
GP0 that assembles into trimers in the ER. Each GP0 subunit is
then cleaved by the convertase furin in the trans-Golgi to pro-
duce the surface subunit GP1 (130 kDa) and transmembrane
subunit GP2 (24 kDa), which are linked by a disulfide bond
(11). Although the incorporation of GP trimers into viral parti-
cles is necessary for infection, many of these trimers are
released into culture medium because of cleavage of the GP2
transmembrane anchor by tumor necrosis factor -converting
enzyme (12).
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GP1 is divided into core domain and mucin-like domain
(MLD), and the core domain is further divided into the recep-
tor-binding domain (RBD) and glycan cap (Fig. 1A) (13). The
MLD is responsible for the cytotoxic effect (7), and deletion of
this domain increases GP processing and incorporation into
retroviral particles, resulting in higher transduction efficiency
(13). GP2 contains an internal fusion loop, two heptad repeats
(HR1 and HR2) connected by a functionally important linker,
and a transmembrane domain. GP1 is responsible for attach-
ment to host cells, and GP2 is responsible for mediating fusion
of the virus envelope with the host endosomal membranes. In
fact, EBOV infection requires minimal incorporation of GP on
the surface of virions; increasing GP incorporation in virions
can strongly reduce viral transduction efficiency (14).
Filovirus GPs are heavily glycosylated with both N-linked
and O-linked glycans, and glycans contribute over one-third of
their molecular weight (8). The Zaire EBOV GP1 and GP2 sub-
units have 15 or two N-linked glycosylation sites (NGSs) (Fig.
1A) (15). The MLD itself has eight NGSs and 80 O-linked
glycosylation sites (3). By pseudotyping the GP-defective vesic-
ular stomatitis virus with EBOV GPs, it was reported that,
although the 15 GP1 NGSs protect EBOV from neutralizing
antibodies, they are dispensable for GP expression and function
(16). In contrast, the two GP2 NGSs, Asn563 and Asn618, are
indispensable for EBOV GP-mediated vesicular stomatitis virus
transduction (17). However, it remained unclear how Asn563
and Asn618 determine the GP function.
N-glycosylation starts in the ER on asparagine residues with a
consensus NXS/T motif and is completed in the Golgi by add-
ing a heterogeneous mixture of high-mannose (Man), hybrid,
and complex oligosaccharides (18). This process involves a
number of chaperones, glycoside hydrolases, and oxidoreduc-
tases to promote protein folding and maturation. Calnexin
(CNX) and calreticulin (CRT) comprise a fundamental ER
chaperone system, ensuring that glycoproteins achieve proper
folding after glycosylation by interacting with their polypeptide
precursors in glycan-dependent or independent manners (19).
Currently, it is still unclear whether EBOV GPs employ the
CNX/CRT cycle for expression and how they interact with
CNX/CRT.
Previously, envelope glycoprotein (Env)-defective (Env)
murine leukemia viruses were pseudotyped with EBOV GPs to
study their function (13). Here we used Env HIV type 1
(HIV-1)asasurrogateinfectionsystemtostudyEBOVGPN-gly-
cosylation. In combination with site-directed mutagenesis
and biochemical approaches, we have not only confirmed the
important role of Asn563 and Asn618 but also collected mecha-
nistic insight into why they are so critical for GP function.
Results
The role of Asn563/Asn618 in GP processing and virion
incorporation
To reduce cytotoxicity, we used MLD-deleted (MLD) GP in
most of our experiments to study GP activity. We first com-
pared MLD-GP expression and activity with the full-length
(FL) GP. All GP proteins were fused to an N-terminal FLAG tag,
so their expressions were detectable with an anti-FLAG anti-
body. 293T cells were transfected with an FL-GP or MLD-GP
expression vector plus a Env HIV-1 proviral vector expressing
the firefly luciferase report gene (pNL-LucEnv). After 48 h,
pseudovirions were collected and quantified, and the viral
transduction efficiency was measured by infecting Vero cells. In
addition, transfected cells as well as pseudovirions were lysed,
and the levels of viral protein expression were determined by
Western blotting.
As reported, we found that, because of the heavy O- and
N-glycosylation of the MLD in the Golgi, FL-GP1 exhibited a
higher molecular weight than FL-GPpre, whereas MLD-GP1
exhibited a lower molecular weight than MLD-GPpre (Fig.
1B). In addition, MLD-GP exhibited higher levels of protein
expression and were more effectively processed and pack-
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Figure 1. A functional comparison of EBOV FL-GP and MLD-GP. A, schematic of EBOV GP. GP1, GP2, core, MLD, RBD, and glycan cap (Cap) regions in FL GP
are indicated. Numbers indicate amino acid residues. NGSs are marked as Y. B, FL-GP and MLD-GP expression in cells and their incorporation into HIV-1 virions
were detected by Western blotting. GPpre, EBOV GP precursor; p24 and p55, HIV-1 Gag antigens. GP proteins were detected by an anti-FLAG antibody, and actin
and HIV-1 Gag proteins were detected by their specific antibodies. C, comparison of GP-mediated HIV-1 transduction. Virions were produced from 293T cells
after transfection with the pNL-Luc-Env and MLD-GP or FL-GP expression vectors. Vero cells were infected with these viruses after normalization of the p24
Gag proteins, and viral transduction efficiency was quantitated by measuring the cellular luciferase activities. Results are presented as relative values. Error bars
represent standard deviations calculated from three experiments.
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aged into HIV-1 particles than FL-GP (Fig. 1B). Moreover,
MLD-GP dramatically increased HIV-1 transduction com-
pared with FL-GP (Fig. 1C). These results demonstrate that
MLD-GP provides a more effective and convenient system to
study GP biochemistry and function.
Next, each of the nine NGSs on MLD-GP were deglycosy-
lated by replacing Asn with Gln, creating nine mutants: N40Q,
N204Q, N228Q, N238Q, N257Q, N268Q, N296Q, N563Q, and
N618Q. When their expression in cells and HIV-1 pseudoviri-
ons was determined, it was found that none of these single
mutations reduced GP expression and processing, except for
N563Q and N618Q, which reduced processing (Fig. 2A, lanes
1–10). In addition, both the N618Q and N563Q mutations dra-
matically reduced GP incorporation (Fig. 2B, lanes 9 and 10).
To continue this investigation, a number of combinative and
accumulative mutations were created. For example, N40Q/
204Q, N296Q/563Q, and N563Q/618Q have the two indicated
NGSs mutated; N40Q-228Q, N40Q-238Q, N40Q-257Q,
N40Q-268Q, N40Q-296Q, N40Q-563Q, N40Q-618Q,
N257Q-618Q, and N257Q-296Q have three to nine NGSs
mutated. A more detailed description of these mutations is pro-
vided in supplemental Table 1. It was found that the five N-ter-
minal NGSs (Asn40 to Asn257) were not required for GP cleav-
age (Fig. 2A, lanes 11–16). However, when the accumulated
mutations were extended to Asn268 and beyond, GP1 expres-
sion either decreased or became undetectable in both cells and
virions (Fig. 2, A and B, lanes 17–20). When the five C-terminal
NGSs (Asn257, Asn268, Asn296, Asn563, and Asn618) were
mutated (N257Q–N618Q), GP1 became undetectable in cells
and virions (Fig. 2, A and B, lane 23); when Asn563 and Asn618
were mutated (N563Q/N618Q), GP1 showed the same defect
(Fig. 2, A and B, lane 25). Together, these results demonstrate
that Asn563/Asn618 are crucial for EBOV GP proteolytic cleav-
age and incorporation.
Role of Asn563/Asn618 in GP demannosylation
During N-glycosylation, the preassembled oligosaccharide
(Glc3Man9GlcNAc2) needs to be further processed after being
attached to NGSs. Among the nine Man residues, four are 1,2-
linked and are sequentially removed by class I -mannosidases.
The other five are either 1,3- or 1,6-linked, and two of these
are removed by a class II -mannosidase. Endoglycosidase H
(Endo H) cleaves each structure of these oligosaccharides as
they are processed until the class II enzyme removes the two
Man residues. Thus, Endo H-sensitive and -resistant glycopro-
teins contain high-Man or low-Man sugars, respectively.
We used Endo H treatment to determine how NGSs regulate
GP demannosylation. As expected, GPpres from both MLD-
GP and FL-GP were sensitive to Endo H because it contains
unprocessed Man residues; GP1 was resistant to Endo H
GPpre
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Figure 2. Mutational analysis of EBOV GP NGSs. A and B, 293T cells were transfected with the WT or the indicated MLD-GP mutant expression vectors.
Virions were purified from cell culture supernatants by ultracentrifugation. Cells (A) and virions (B) were lysed and analyzed by Western blotting.
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because its Man residues were already processed (Fig. 3A, lanes
1, 2, 17, and 18). Removal of the four N-terminal NGSs (Asn40
to Asn238) or the three middle NGSs (Asn257 to Asn296)
increased the Endo H-resistant band (Fig. 3A, lanes 3, 4, 7, and
8), whereas removal of the five C-terminal NGSs (Asn257 to
Asn618) almost completely eliminated the Endo H-resistant
band (Fig. 3A, lanes 5 and 6). Importantly, when Asn563 and/or
Asn618 were removed (N563Q, N618Q, and N563Q/N618Q),
the Endo H-resistant band was eliminated (Fig. 3A, lanes 9 –16,
19, and 20). These results demonstrate that Asn563 and Asn618
are required for demannosylation.
To understand how demannosylation affects GP function, we
treated cells with kifunesine (KIF), a potent inhibitor of class I
mannosidases that is primarily used in cell culture to make high-
Man glycoproteins (20). It was found that the treatment com-
pletely eliminated the Endo H-resistant EBOV GP, indicating that
KIF effectively blocked demannosylation (Fig. 3B). In addition, KIF
reduced HIV-EBOV GP transduction in a dose-dependent man-
ner without reducing the levels of the GP incorporation (Fig. 3, C
and D). These results demonstrate that demannosylation is
required for EBOV GP function.
The role of Asn563/Asn618 in GP oligomerization
To understand whether the N563Q and N618Q mutations
have altered the GP conformation, we used flow cytometry to
determine GP interaction with two conformation-dependent
anti-EBOV GP mAbs, KZ52 (21) and 13C6 (22). We first used a
conformation-independent anti-FLAG antibody to detect WT,
N563Q, N618Q, and N563Q/N618Q MLD GP proteins and
found a similar level of surface expression (Fig. 4, A and B).
However, the N563Q mutation reduced KZ52 and 13C6
binding by 25% or 50%, and the N618Q mutation also did so
at relatively modest levels (Fig. 4, A and B). These results are
consistent with a previous report (17), suggesting that
Asn563/Asn618 are important for maintaining the natural
conformation.
Next we tested whether Asn563 and Asn618 play a role in GP
oligomerization. Asn563 is located in the proximity of the trimer
interface and may play a role in trimer stabilization (23, 24). The
Asn618 glycan is an unusual sugar that is present in the HR2
region, and the currently solved crystal structures of GP have
not extended to this region. However, it is possible that this
sugar might create some steric hindrance to trimer formation
or stabilization. MLD-GP and its mutants N563Q, N618Q, or
N563/618Q were expressed in 293T cells, and soluble GPs were
purified from the culture medium. It was found that a single
monomer GP band was detected at a similar level in the reduc-
ing gel, indicating that Asn563 and Asn618 are not required for
GP shedding (Fig. 4C). However, a striking difference was found
in the non-reducing gel. Trimers and monomers were
detected from MLD-GP proteins at a ratio of 1.75:1, mono-
mers were exclusively detected from N563Q, trimers were
exclusively detected from N618Q, and trimers and mono-
mers were also detected from N563Q/N618Q but at a ratio
0.44:1 (Fig. 4, C and D). These results demonstrate that
Asn563 increases, whereas Asn618 inhibits, trimer formation,
and the N563Q/N618Q double mutation results in an overall
reduction in trimer formation.
Role of CNX/CRT in GP expression
CNX is a type I transmembrane protein with 592 amino
acids, and CRT is its soluble paralog, sharing 39% sequence
GPpre
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Figure 3. Effect of demannosylation on EBOV function. A, analysis of GP sensitivity to Endo H. 293T cells were transfected with the indicated GP expression
vectors. Cell lysate was either treated with Endo H or left untreated and analyzed by Western blotting. B, KIF increases GP sensitivity to Endo H. 293T cells
transfected with the MLD-GP expression vector were treated with 50 M KIF or remained untreated. Lysate from these cells was treated with Endo H or left
untreated and analyzed by Western blotting. C, KIF inhibition of GP-mediated HIV-1 transduction. 293T cells producing HIV-1 luciferase reporter viruses
pseudotyped with EBOV MLD-GP were treated with the indicated amounts of KIF. Viral transduction was measured by infecting Vero cells. Error bars represent
standard deviation from three experiments. D, KIF does not affect GP expression in HIV-1 virions. HIV-1 pseudovirions produced in C were purified by
ultracentrifugation, and viral protein expression in these virions was determined by Western blotting.
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identity with 417 amino acids. Their role in EBOV GP biosyn-
thesis has not been tested.
First, we determined whether EBOV GP expression depends
on CNX/CRT. The CNX and/or CRT genes were knocked out
from 293T cells using CRISPR/Cas9 technology (Fig. 5A), gen-
erating two single KO cell lines, CNX and CRT, and one
double KO cell line,  (Fig. 5B). When EBOV GP expression
was determined in these KO cells, it was found that GP expres-
sion was reduced in both CNX and CRT cells, and the
expression was further reduced in  cells (Fig. 5C). In addi-
tion, when CNX and CRT expression was gradually restored in
 cells by co-transfection with their expression vectors, GP
expression was increased in a dose-dependent manner (Fig. 5, D
and E). These results demonstrate that both CNX and CRT
increase EBOV GP expression.
Second, we determined whether EBOV GPs interact with
CNX or CRT. MLD-GPs were expressed in WT, CNX,
CRT, and  cells, and protein complexes were pulled down
using anti-FLAG antibodies. It was found that the endogenous
CNX could be pulled down from WT and CRT but not CNX
and  cells (Fig. 6A). These results demonstrate that GPs
interact with CNX in a CRT-independent manner. To detect
the interaction with CRT, these cells were co-transfected with a
CRT expression vector, and the experiment was repeated. It
was found that, although similar levels of CRT were detected in
these cells, CRT could only be pulled down from cells express-
ing GPs (Fig. 6B). In addition, more CRT proteins were pulled
down from WT and CNX than CRT and  cells. These
results demonstrate that GPs also interact with CRT in a CNX-
independent manner.
Figure 4. Influence of Asn563/Asn618 mutations on EBOV GP conformation. A and B, detection of GP interaction with conformation-dependent neutralizing
antibodies was performed using flow cytometry. 293T cells were transfected with the indicated expression vectors. Cells were stained with anti-FLAG, KZ52, or
13C6 antibodies and analyzed by FACScan. The levels of positive populations are shown in A, and the mean fluorescence intensity (MFI) in these populations
is shown in B. Error bars represent standard deviation calculated from three experiments. Ctrl, control. C, analysis of GP oligomerization. 293T cells were
transfected with the indicated MLD-GP expression vectors. Cellular proteins were resolved with non-reducing or reducing gels and analyzed by Western
blotting. The trimer and monomer bands are labeled. D, the intensity of trimer and monomer bands in the Western blot (C) was quantified with ImageJ. Their
relative ratios were then calculated and are presented.
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Third, we determined how GPs interact with CNX/CRT.
MLD-GP and its NGS-null mutant N40Q–N618Q was
expressed in WT, CNX, or CRT cells, and protein com-
plexes were pulled down using anti-CNX or anti-CRT antibod-
ies. It was found that both CNX and CRT could specifically pull
down MLD-GP and N40Q–N618Q in WT but not CNX or
CRT cells (Fig. 6, C and D). In addition, more N40Q–N618Q
proteins were pulled down than WT proteins despite N40Q–
N618Q protein expression being lower than the WT protein.
These results demonstrate that both CNX and CRT specifically
interact with EBOV GP in a N-glycan-independent manner.
Role of Asn563/Asn618 in FL-GP processing and incorporation
We have shown that N563Q/N618Q mutations synergisti-
cally reduce MLD-GP processing and incorporation into
HIV-1 virions. We then used FL-GP and EBOV-like particles
(E-VLPs) to confirm these observations.
FL-GP and its mutants N40Q–N618Q, N40Q–N238Q,
N563Q, N618Q, or N563Q/N618Q were expressed with the
EBOV matrix protein VP40 in 293T WT cells, and E-VLPs were
purified from the culture supernatants by ultracentrifugation.
After that, viral protein expression in cells and E-VLPs was
determined by Western blotting. As shown previously in Fig. 2,
the glycan-null N40Q–N618Q mutant was poorly expressed or
incorporated, N40Q–N238Q mutant expression, processing,
and incorporation were not affected, and the N563Q and
N618Q mutations synergistically reduced FL-GP processing
and incorporation into E-VLPs (Fig. 7, lanes 1– 6). These results
further confirm the important role of Asn563 and Asn618 in GP
processing and incorporation.
We also performed similar experiments in CNX and/or CRT
KO cells after expressing VP40 and MLD-GP bearing N40Q–
N618Q, N40Q–N238Q, N563Q, N618Q, or N563Q/N618Q
mutations. In general, much lower levels of GP expression were
detected from these KO cells, particularly in double KO cells,
which confirms the requirement of CNX/CRT for GP expres-
sion (Fig. 7, lanes 7–30). In addition, GP processing and incor-
poration were more strongly inhibited by these mutations in
these KO cells, particularly in the double KO cells. Together,
these results further demonstrate the important role of Asn563/
Asn618 in GP processing and incorporation.
The role of Asn563/Asn618 in GP-mediated HIV-1 transduction
To understand how these mutations affect GP function, we
determined the transduction efficiency of HIV-1-EBOV GP
particles produced from 293T WT, CNX, CRT, or  cells.
Viruses were pseudotyped with FL-GP or MLD-GP bearing
N40Q–N618Q, N40Q-N238Q, N563Q, N618Q, or N563Q/
N618Q mutations. First, we analyzed how CNX/CRT affects
GP function. It was found that the transduction efficiency by
MLD GP was synergistically reduced by CNX and CRT KO
(Fig. 8A). This result confirms the important role of CNX/CRT
in EBOV GP biosynthesis. Second, we analyzed how these gly-
cans affect GP function in WT cells. It was found that the
N40Q–N238Q and N563Q mutations increased, the N618Q
mutation decreased, and the N40Q–N618Q and N563Q/
N618Q mutations almost completely disrupted the FL-GP and
MLD-GP activities (Fig. 8, B and C). Last, we analyzed how
these glycans affect GP function in CNX and/CRT KO cells.
Similar results were found in these KO cells as in WT cells. For
example, the N40Q–N238Q and N563Q mutants showed a
comparable activity to the WT protein, which was higher than
the N618Q mutant, and both the N40Q–N618Q and N563Q/
N618Q mutants almost completely lost their activities (Fig. 8C).
In addition, the difference between the active and inactive
mutant activities was much smaller in double KO than in single
KO cells (Fig. 8C). Together, these results support that Asn563
and Asn618 synergistically regulate EBOV GP maturation,
which determines its function.
Discussion
In this report, we have collected new insight into how Asn563
and Asn618 contribute to the functionality of EBOV GP. GP1 is
divided into MLD, RBD, and glycan cap domain (Fig. 1A). Its
crystal structure shows that the heavily glycosylated glycan cap
and MLD surround the RBD, and a thick layer of oligosaccha-
ride cloaks most of the structure (24). It was suggested that
N-linked glycans attached to GP1 might not be absolutely
required for GP folding and that their function could be com-
plemented by the other glycans in the MLD (16). When we
deleted these N-linked glycans in MLD-GP (N40Q–N296Q),
1 167 178 592
ctgctttctaaaacaccagaactcaacctggatcag
L  L  S  K  T  P  E  L  N  L  D  Q
CNX
gRNA PAM
1 51 62 417
ctcagttccggcaagttctacggtgacgaggagaaa
L  S  S  G  K  F  Y  G  D  E  E  K
CRT
gRNA PAM
CNX
CNX
GPpre
GP1
Actin
1 2 3 4 5 6
CRT
CRT
GPpre
GP1
Actin
1 2 3 4 5
A
B
D E
C
95 kD
72 kD
55 kD
43 kD
CNX
CRT
Actin
293T
55 kD
72 kD
43 kD
GPpre
GP1
Actin
293T
Figure 5. Requirement of CNX/CRT for EBOV GP expression. A, schematic
of CNX and CRT KO by CRISPR/Cas9. The targeted gene locus of CNX and CRT is
indicated by arrows. Lowercase letters present nucleotide sequences, upper-
case letters represent amino acid sequences, guide RNA (gRNA) target
sequences are shown in green, and the protospacer-adjacent motif (PAM)
sequences are shown in red. Numbers indicate amino acid residues. B, detec-
tion of CNX, CRT, and actin expression by Western blotting. CNX, CNX KO
cells; CRT, CRT KO cells; , CNX/CRT double KO cells. C, comparison of
MLD-GP expression in the indicated cells by Western blotting. D and E, res-
cue of GP expression in CNX/CRT double KO cells by ectopic expression of CNX
or CRT. Cells were transfected with MLD-GP and increasing amounts of CNX
(D) or CRT (E) expression vectors, and protein expression was determined by
Western blotting.
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we found that not only were the total levels of GP expression
reduced, but GP processing and virion incorporation were also
inhibited (Fig. 2, A, lane 18, and B, lane 18). Thus, our results
demonstrate that these N-linked glycans become indispensable
for EBOV GP expression and function when MLD is not pres-
ent, confirming that the glycan cap and MLD play a comple-
mentary role in GP folding.
Unlike GP1, and independent of the MLD, N-linked glycans
in GP2 are required for EBOV GP function. Recent reports
investigating the removal of NGSs from the FL-GP backbone
show that, although an N563D mutation can enhance viral
entry by 2-fold and an N618D mutation can decrease viral entry
by 2-fold, an N563D/N618D double mutation is able to com-
pletely disrupt viral entry (17). Consistently, we also found that
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GPpre
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C D
1 2 3 4 5
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Anti-FLAG
Pull-down
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GP1
∆MLD-GP-FLAG
293T WT
1 2 3 4 5
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Anti-FLAG
Pull-down
CRT
CRT
GPpre
GP1
∆MLD-GP-FLAG
CRT-Myc
293T WT
Figure 6. Interaction of EBOV GP with CNX/CRT. A and B, detection of GP interaction with CNX (A) or CRT (B). The indicated cells were transfected with
MLD-GP expression vector alone (A) or in the presence of CRT expression vector (B). Proteins were pulled down with anti-FLAG beads and analyzed by
Western blotting. C and D, role of NGSs in GP interaction with CNX and CRT. The indicated cells were transfected with WT MLD-GP or its N40Q-618Q mutant
expression vector. Proteins were pulled down with anti-CNX (C) or anti-CRT (D) antibodies and analyzed by Western blotting.
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Figure 7. Comparison of EBOV GP expression and incorporation into E-VLPs. 293T WT, CNX, CRT, and  cells were transfected with the indicated
FL-GP or MLD-GP expression vectors and an EBOV matrix VP40 expression vector. E-VLPs were recovered from cell culture supernatants and purified by
ultracentrifugation. Protein expression in cells and E-VLPs was analyzed by Western blotting.
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viral entry was slightly increased by an N563Q mutation,
slightly decreased by an N618Q mutation, and almost com-
pletely disrupted by an N563Q/N618Q mutation (Fig. 8). Thus,
there is conclusive evidence that glycans at Asn563 impede but
glycans at Asn618 enhance viral entry, but simultaneous degly-
cosylation of both residues completely disrupts viral entry.
Although EBOV GP has a thick coating of oligosaccharides,
there are vulnerable regions that are exposed to neutralizing
antibodies. For example, the neutralizing antibodies KZ52 and
16F6 bind to both GP1 and GP2 in their prefusion complex,
which may prevent their conformational rearrangements (23,
24). Their GP1 epitope has been mapped to residues 42– 44, and
their GP2 epitopes are in the internal fusion loop and HR1.
Asn563 and Asn618 are located in HR1 or HR2, respectively. As
reported before (17), we found that Asn563 and/or Asn618 degly-
cosylation reduced GP binding to KZ52 and another neutraliz-
ing antibody, 13C6 (Fig. 4, A and B). Thus, glycans at Asn563 and
Asn618 should play an important role in GP conformational
changes from prefusion to postfusion state.
To understand more about Asn563 and Asn618, we performed
several biochemical experiments. First, we found that both the
N563Q and N618Q single mutations reduced, but the N563Q/
N618Q double mutation completely blocked, GP protease
cleavage (Figs. 2A and 7). Second, we found that the N563Q,
N618Q, and N563Q/N618Q mutations all reduced GP incor-
poration (Figs. 2B and 7). Third, we found that the N563Q
mutation strongly inhibited, but the N618Q mutation strongly
promoted, GP trimerization; the N563Q/N618Q mutation
caused a mixed phenotype by reducing trimers and increasing
monomers (Fig. 4C). Nevertheless, they are not required for
interaction with the ER chaperones CNX/CRT (Fig. 6).
Together, these results further demonstrate that Asn563/
Asn618 are indeed important for the maintenance of crucial GP
conformations for infection.
We also found that the N563Q, N618Q, and N563Q/N618Q
mutants became highly sensitive to Endo H, indicating that they
should contain high-Man sugars (Fig. 3A). Demannosylation is
an essential step during N-glycosylation, which remolds the
Figure 8. Effect of NGS mutations on EBOV GP-mediated HIV-1 transduction. A–C, HIV-1 pseudovirions were produced from 293T WT, CNX, CRT, and 
cells after transfection with pNL-LucEnv and the MLD-GP expression vector (A), from WT cells after transfection with the HIV-1 vector and the indicated
FL-GP expression vectors (B), and from WT, CNX, CRT, and  cells after transfection with the HIV-1 vector and the indicated MLD-GP expression vectors
(C). HIV-1 pseudovirions were collected from cell culture supernatants and normalized by the HIV-1 p24 antigen. The transduction efficiency was then
determined by infecting Vero cells. Results are presented in relative values. Error bars represent standard deviation calculated from three experiments.
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sugar chains by removing Man residues and adding other sug-
ars. N-glycosylation produces three types of structures: high-
Man, hybrid, and complex (25). The high-Man and some hybrid
types contain more Man residues than the complex type, which
are cleavable by Endo H. Previously, it has been taken as com-
mon knowledge that glycoproteins with high-Man structures
could not be released from the ER, so Endo H resistance was
used as a marker for trafficking to the Golgi (26). However,
recent findings have uncovered that many glycoproteins with
high-Man sugars are indeed secreted to the cell surface, sug-
gesting that these proteins can exit from the ER (27). Interest-
ingly, it was reported before that loss of two NGSs on rabies
virus GPs also resulted in production of high-Man glycoprotein
without affecting cell surface expression (28, 29). In addition, it
was reported that high-Man glycans on Env reduce HIV-1
infectivity and block mucosal transmission of simian immuno-
deficiency virus (SIV) (30 –32). Moreover, SIV Env incorpora-
tion is profoundly impaired when Env is modified by high-Man
structure glycans (32). To understand whether the high-Man
structure also reduces EBOV GP-mediated transduction, we
treated viral producer cells with KIF to block demannosylation.
We found that the treatment indeed not only blocked deman-
nosylation (Fig. 3B) but also reduced transduction in a dose-de-
pendentmanner(Fig.3C).Thus,becausethehigh-Manoligosac-
charides represent an incompletely processed, immature
N-glycan structure, they may negatively modulate EBOV GP
function via a similar mechanism as that in HIV-1 and SIV.
We observed a striking inconsistency between levels of
GP incorporation and transduction efficiency. For example,
although both the N563Q and N563Q/N618Q mutants were
poorly incorporated (Fig. 2B, lanes 9 and 25), only the N563Q/
N618Q mutant significantly lost transduction efficiency, and
the N563Q mutant showed a slight increase in efficiency rela-
tive to the WT protein (Fig. 8). As introduced earlier, EBOV
infection requires very low levels of GP on the virus surface, and
high levels of GP strongly reduce viral titers (14). Thus, our
results confirm that a very low level of incorporated GP is suf-
ficient for EBOV infection. In addition, our results also suggest
that levels of EBOV GP incorporation should not be viewed as a
reflective criterion for its transduction efficiency.
In summary, we have observed dramatic changes in EBOV
GP biochemical properties via deglycosylation of Asn563/
Asn618, which include processing, demannosylation, and oligo-
merization. These changes synergistically affect EBOV GP
conformation and disrupt viral entry. Thus, Asn563/Asn618 rep-
resent an attractive target to block EBOV infection.
Experimental procedures
Enzyme, inhibitor, and antibodies
Endo H was purchased from New England Biolabs. KIF,
radioimmune precipitation assay (RIPA) lysis buffer, anti-
FLAG M2 antibodies, anti-FLAG affinity gel, and anti-HA anti-
bodies were purchased from Sigma-Aldrich. Anti-actin and
anti-C-Myc monoclonal antibodies were purchased from Santa
Cruz Biotechnology. Rabbit anti-calnexin polyclonal antibod-
ies were purchased from Enzo Life Science. Anti-calreticulin
monoclonal antibodies were purchased from Cell Signaling
Technology. Anti-Zaire EBOV VP40 rabbit polyclonal anti-
body was purchased from Sino Biological. Allophycocyanin-
conjugated mouse anti-FLAG antibody was purchased from
Columbia Biosciences. KZ52 and 13C6 antibodies were pur-
chased from IBT Bioservices. Phycoerythrin-conjugated goat
anti-human IgG secondary antibody was purchased from Santa
Cruz Biotechnology. HRP-conjugated secondary antibodies for
Western blotting were purchased from Jackson ImmunoRe-
search Laboratories. The anti-HIV-1 Gag monoclonal antibody
(183) was obtained from the National Institutes of Health AIDS
Research and Reference Reagent Program.
Plasmids
The HIV-Luc reporter proviral vector pNL-Luc-Env was
described before (33). The N-terminal FLAG-tagged EBOV
MLD GP expression vector was obtained from Shan-Lu Liu
(University of Missouri). The human codon-optimized Cas9
expression vector was obtained from George M. Church (Har-
vard Medical School) through Addgene. pEGFP-C1 was pur-
chased from Clontech. A plasmid expressing the full-length
EBOV Zaire subtype matrix VP40 was purchased from Sino
Biological.
To create calnexin- and calreticulin-expressing constructs,
the nucleotide sequences encoding HA-tagged calnexin and
C-Myc-tagged calreticulin were amplified by PCR from
pMSCVneo-CANX (34) and pCMV6-CRT (Origene), respec-
tively, and subcloned into the pCAGGS vector. To generate the
FL-GP expression vector, the coding sequence for GP MLD was
first synthesized and then inserted into the MLD-GP expres-
sion vector via overlapping PCR. Single N-glycosylation
mutants were constructed by asparagine-to-glutamine substi-
tution using the QuikChange site-directed mutagenesis kit
(Agilent Technologies). Single N-glycosylation mutants were
subjected to further rounds of mutagenesis to create multiple
sites mutants. All vectors were sequenced to confirm the cor-
rect sequences. Detailed procedures for the construction of the
plasmids are available upon request.
Cells
The 293T, HeLa, and Vero cell lines were purchased from the
ATCC and maintained in DMEM supplemented with 10% fetal
bovine serum, 100 units/ml penicillin, and 100 g/ml strepto-
mycin (Gibco) at 37 °C in 5% CO2.
Virus production
Lentiviral pseudovirions bearing EBOV GP were generated
as described before with minor modifications (35). Briefly, a
total of 4  106 293T cells were seeded in 10-cm dishes and
cultured overnight. Five micrograms of the plasmid encoding
either the WT or mutant EBOV GP and 5 g of pNL-Luc-Env
were mixed with 30 l of PEI (Polysciences, 1 g/l) in 500 l of
serum-free DMEM. After a 15-min incubation at room temper-
ature, the transfection complexes were added to the cells. The
medium was replaced with fresh medium 6 h after transfection.
Forty-eight hours later, the culture supernatants were col-
lected, clarified by low-speed centrifugation, and passed
through a 0.45-m syringe filter to remove any cell debris. The
virion-containing supernatants were either used to infect target
Functional characterization of EBOV GP N-glycosylation
5868 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292 • NUMBER 14 • APRIL 7, 2017
 at U
N
IV
 O
F N
E
B
R
A
SK
A
 - L
incoln on N
ovem
ber 30, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
cells or stored at 80 °C. E-VLPs were generated by the same
method, except that the pNL-Luc-Env vector was replaced
with a VP40-encoding plasmid. To analyze the levels of EBOV
GP incorporation, supernatants containing virions were centri-
fuged at 25,000 rpm at 4 °C for 2 h using a Beckman SW-32Ti
rotor. Viral pellets were resuspended in RIPA buffer and sub-
jected to Western blotting analysis.
EBOV transduction assay
A total of 2  104 Vero cells were seeded in each well of
96-well plates 24 h prior to infection. An equal amount of pseu-
doviruses (normalized by HIV p24Gag) was inoculated into
these cells. After 48 h of infection, the culture medium was
removed, and cells were lysed in 100 l of lysis buffer (Pro-
mega). Luminescence was measured with a luciferase assay kit
(Promega) and a TD-20/20 luminometer (Turner Designs).
Western blotting and immunoprecipitation
After being washed three times with cold PBS, transfected
cells were lysed in RIPA buffer supplemented with 1 mg/ml
protease inhibitor mixture (Roche) for 30 min on ice. Lysate
was centrifuged at 12,000  g for 10 min at 4 °C to remove any
debris. Clarified supernatants were mixed with DTT-contain-
ing sample loading buffer (Solarbio), heated at 95 °C for 5 min,
and then resolved by PAGE in 10% gels under reducing condi-
tions. Some samples were subjected to Endo H treatment
before applying them to the SDS-PAGE. To do so, a total of 20
g of lysate was first denatured by heating at 100 °C for 10 min
in denaturing buffer. Denatured proteins were added to a 20-l
reaction system containing 2 l of GlycoBuffer and 1000 units
of Endo H and incubated at 37 °C for 1 h.
For blue native PAGE, samples were prepared in native
PAGE buffer (Life Technology) and separated on Novex 3–12%
BisTris gels (Invitrogen) according to the protocol of the
manufacturer.
For immunoprecipitation, clarified cell lysate was incubated
with antibodies followed by addition of protein G-Sepharose
beads (Pierce) or directly with anti-FLAG M2 monoclonal anti-
body-coupled beads (Sigma) at 4 °C for 4 h with rotation. Beads
were washed twice with cold PBS containing 1% Triton X-100,
followed by one more washing with PBS alone. Proteins were
then eluted from beads by boiling and separated under dena-
turing conditions.
For Western blotting, gels from reducing or non-reducing
electrophoresis were transferred to PVDF membranes. Mem-
branes were briefly blocked with TBS containing 5% skim milk
and 0.1% Tween 20 and then incubated with primary antibodies
for 1 h at room temperature by the following dilutions: anti-
FLAG antibody, 1:2000; anti-HA antibody, 1:3000; anti-Myc
antibody, 1:1000; anti-CNX antibody, 1:1000; anti-CRT anti-
body, 1:1000; and anti-HIV p24 antibody, 1:3000. After being
washed further with TBS containing 0.1% Tween 20, mem-
branes were incubated with HRP-conjugated secondary anti-
bodies at a 1:10,000 dilution. Chemiluminescence was detected
by incubating the membrane with SuperSignal substrate
(Pierce).
Gene knockout
The CRISPR/Cas9 system was employed to knock out CNX
and/or CRT genes in 293T cells as described before (36, 37).
Briefly, a DNA fragment that contained the U6 promoter, a
19-bp target sequence specific for CNX or CRT, a guide RNA
scaffold, and a U6 termination signal sequence was synthesized
and subcloned into the pGEM-T Easy vector (Promega). The
vector was transfected with the human codon-optimized Cas9
expression vector and pEGFP-C1 into 293T cells. Twenty-four
hours later, GFP-positive cells were isolated by fluorescence-
activated cell sorting and subjected to cloning by limiting dilu-
tion. After 10 –14 days, knockout clones were identified after
screening by Western blotting.
Flow cytometry
For cell surface GP staining, a total of 1  106 293T cells were
transfected with EBOV GP expression vector. Forty-eight
hours later, cells were harvested and washed twice with PBS
containing 0.1% bovine serum albumin. Cells were stained with
allophycocyanin-conjugated anti-FLAG antibody for 30 min at
4 °C, washed three times, fixed in 4% paraformaldehyde, and
analyzed by FACScan (BD Biosciences). Cells were also incu-
bated with KZ52 or 13C6, followed by staining with phyco-
erythrin-conjugated anti-human IgG antibodies. The negative
gate was defined with untransfected cells stained with the same
antibody.
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